Clomiphene
Ovulation Stimulants, Synthetic
- Drug class
- Ovulation Stimulants, Synthetic
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
Overview
Plain-language summary, compiled from the cited regulatory records
Clomiphene is a medication classified as a synthetic ovulation stimulant [1]. It is approved for the treatment of ovulatory dysfunction in women who are trying to become pregnant [1]. Before starting clomiphene citrate therapy, any conditions that could prevent pregnancy should be addressed or ruled out [1]. This medication is often considered for patients experiencing issues such as polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, or amenorrhea following the use of oral contraceptives [1].
Clomiphene is available under various brand names [1]. The number of adverse event reports for clomiphene in the last 12 months is not available in the provided data [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | September 18, 2025 |
USUnited States· FDA
1 product
Uses
INDICATIONS & USAGE
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS: Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.
Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5 th day of the cycle.
Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). ) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: Patients who are not pregnant.
Sources & citations
- [1]FDA DailyMed · 086eace1-51db-4d… · revised September 18, 2025 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.